Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Real-world 12-month outcomes of risdiplam in spinal muscular atrophy types 2 and 3

Background: Spinal muscular atrophy is a progressive genetic neuromuscular disorder characterized by degeneration of lower motor neurons and progressive muscle weakness. Risdiplam, an oral survival motor neuron 2 splicing modifier, has demonstrated efficacy in clinical trials; however, real-world data in older and chro...

Eric Dupont, C. Camelo, R. Mendonça et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.